"<!DOCTYPE html PUBLIC \"-//W3C//DTD XHTML 1.0 Transitional//EN\" \"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd\"><html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:v=\"urn:schemas-microsoft-com:vml\" xmlns:o=\"urn:schemas-microsoft-com:office:office\"><head><title>REVLIMID</title><meta http-equiv=\"Content-Type\" content=\"text/html;\" charset=\"utf-8\"><meta name=\"viewport\" content=\"width=device-width, initial-scale=1\"><meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\"><meta name=\"format-detection\" content=\"telephone=no\"><!--[if !mso]><!--><link href=\"https://fonts.googleapis.com/css?family=Roboto:400,400i,700,700i\" rel=\"stylesheet\"><link href=\"https://fonts.googleapis.com/css?family=Roboto+Condensed:400,400i,700,700i\" rel=\"stylesheet\"><!--<![endif]--><!--[if (gte mso 9)]>\n<o:OfficeDocumentSettings>\n<o:AllowPNG/>\n<o:PixelsPerInch>96</o:PixelsPerInch>\n</o:OfficeDocumentSettings><style type=\"text/css\">/*outlook remove links when they have a empty href */\n.outlookUnderline {\n    text-decoration: underline!important;\n}\nbody,table,td,font{font-family: Helvetica, Arial, sans-serif !important; }</style><![endif]--><style>\n/* CLIENT-SPECIFIC RESETS */\n.ExternalClass { width: 100%; }\n.ExternalClass * { line-height: 100%; }\n\nbody, table, td, a{-webkit-text-size-adjust: 100%; -ms-text-size-adjust: 100%;}\ntable, td{mso-table-lspace: 0pt; mso-table-rspace: 0pt;}\nimg { -ms-interpolation-mode: bicubic; }\n\n\n/* RESET STYLES */\nimg { border: 0; height: auto; line-height: 100%; outline: none; text-decoration: none; }\ntable { border-collapse: collapse !important; }\nbody { height: 100% !important; margin: 0 !important; padding: 0 !important; width: 100% !important; }\n\n/* GENERAL STYLE RESETS */\ntd {border-collapse: collapse !important;}\n#outlook a {padding: 0;}\n.ReadMsgBody { width: 100%; }\n\n/* iOS BLUE LINKS */\na[x-apple-data-detectors] {\n  color: inherit !important;\n  text-decoration: none !important;\n  font-size: inherit !important;\n  font-family: inherit !important;\n  font-weight: inherit !important;\n  line-height: inherit !important;\n}\n\n/* fix tooltip download in gmail*/\n\nimg + div {\n  display: none !important;\n}\n\nimg + div > div {\n  display: none !important;\n}\n\n</style><style>@media only screen and (max-width:479px){.deviceWidth{width:100%!important;padding:0}}</style><style type=\"text/css\" data-premailer=\"ignore\"></style></head><body style=\"margin:0!important; padding:0!important; font-family: Helvetica, Arial, sans-serif;\" topmargin=\"0\" leftmargin=\"0\" marginheight=\"0\" marginwidth=\"0\"><!-- CONTAINER TABLE--><table width=\"100%\" style=\"table-layout: fixed;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\"><!--  WRAPPER TABLE--><table class=\"wrapper\" width=\"600\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><td><!-- HERO START--><div></div><div class=\"hide\"><table class=\"deviceWidth\" width=\"600\" align=\"center\" style=\"margin:0 auto;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tbody><tr><td><a href=\"http://www.revlimid.com/mm-hcp/?utm_source=appature&amp;utm_medium=email&amp;utm_campaign=maintenance_efficacy&amp;utm_content=rev_logo\"><img src=\"img/header/header_img_logo.jpg\" alt=\"Revlimid logo\"></a></td><td><img src=\"./img/header/header_img_text.jpg\"></td></tr></tbody></table></div><!--[if !mso]><!--><div class=\"show\" style=\"display: none;\"><table width=\"100%\" align=\"center\" style=\"text-align: center; border-collapse: collapse;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table width=\"100%\" align=\"center\" style=\"text-align:left;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" valign=\"top\" bgcolor=\"#ffffff\"><table class=\"deviceWidth\" width=\"600\" align=\"center\" bgcolor=\"#ffffff\" style=\"margin:0 auto;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td style=\"padding:0 0 0 0\" valign=\"middle\"><table class=\"deviceWidth\" align=\"left\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"logo-pom center\" valign=\"center\" align=\"center\" height=\"155\" style=\"height:155px;text-align: center; vertical-align: middle;\"><a class=\"center\" href=\"#{logo.url}\" style=\"text-align: center;\" target=\"_blank\"><img src=\"./img/header/header_mobile_logo.png\" width=\"600\" border=\"0\" style=\"width: 100%; display: inline !important;\"></a></td></tr></table><table class=\"hide\" align=\"right\" width=\"600\" height=\"81\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td valign=\"center\" width=\"20\" style=\"width:20px;color:#ffffff;font-size:1px;\">&nbsp;</td><td class=\"center p\" valign=\"center\" style=\"font-size: 14px;font-weight:700;text-align:left;padding:10px 0 0 0;line-height: 1.1;\"><p style=\"mso-table-lspace:0;mso-table-rspace:0; margin:0;text-align:left;\">REVLIMID is indicated for the treatment of patients with MM as maintenance\n  following autologous stem cell transplant (ASCT)\n  <br>\n  <br> REVLIMID is not indicated and is not recommended for the treatment\n  of patients with chronic lymphocytic leukemia (CLL) outside of controlled\n  clinical trials</p></td></tr></table><table class=\"deviceWidth\" align=\"right\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"center\" valign=\"center\"><table class=\"show\" style=\"display:none;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr class=\"me\" style=\"width:0; overflow:hidden; float:left; display:none; max-height:0px; mso-hide:all;\"><td><table class=\"accordionShow\" id=\"partVisible\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"center\"><tr><td width=\"19\"></td><td><table cellspacing=\"0\" cellpadding=\"0\"><tr><td><a href=\"#partVisible\" style=\"display:block; text-decoration:none; color:inherit;\"><div><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"left\" valign=\"top\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"left\" style=\"font-family: 'Roboto', Helvetica, Arial, sans-serif;font-size:14px;line-height:1.4;color:#000000;font-weight:bold; text-decoration:none;\">REVLIMID<sup>&reg;</sup>(lenalidomide) is indicated as <br>maintenance therapy in patients with multiple<br>myeloma (MM) following autologous hematopoietic</td></tr></table></td></tr></table></td></tr><tr><td valign=\"top\"><table align=\"right\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"readMore\" align=\"right\" valign=\"middle\" style=\"font-family: 'Open Sans', sans-serif;font-size:8px;line-height:10px; color:#000000;padding-right:15px;\"></td></tr></table></td></tr><tr><td><div class=\"outerHidden\"><div class=\"innerHidden\"><table width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\" valign=\"top\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"left\" valign=\"top\" style=\"font-family: 'Roboto', Helvetica, Arial, sans-serif;font-size:14px;line-height:1.4;color:#000000;font-weight:bold; text-decoration:none;\">stem cell transplantation (auto-HSCT)\n<br>\n</td></tr><tr><td align=\"left\" valign=\"top\" style=\"font-family: 'Roboto', Helvetica, Arial, sans-serif;font-size:14px;line-height:1.4;color:#000000;font-weight:bold; text-decoration:none; padding-top: 5px;\">REVLIMID is not indicated and is not recommended\n<br>for the treatment of patients with chronic\n<br>lymphocytic leukemia (CLL) outside of controlled clinical trials\n</td></tr></table></td></tr></table></div></div></td></tr><tr><td><div class=\"outerHidden\"><div class=\"innerHidden\"><table width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\" valign=\"top\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"left\" valign=\"top\" style=\"font-family: 'Roboto', Helvetica, Arial, sans-serif;font-size:14px;line-height:1.4;color:#000000;font-weight:bold; text-decoration:none;padding-top: 5px;\">REVLIMID is only available through a restricted distribution program, REVLIMID REMS <sup>Â®</sup><br>\n</td></tr></table></td></tr></table></div></div></td></tr></table></div></a></td></tr></table></td><td width=\"10\"></td></tr></table></td></tr></table><table class=\"close\" width=\"100%\" align=\"center\" style=\"display: none;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table class=\"accordionShow\" id=\"#adv\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><a href=\"#adv\" style=\"display:block; text-decoration:none; color:inherit;\"><div><table width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" height=\"15\" style=\"font-size:0px; line-height:15px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td align=\"center\" valign=\"top\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"25\">&nbsp;</td><td height=\"20\" align=\"right\" valign=\"right\" style=\"font-family: 'Arial', sans-serif;font-size:14px;line-height:23px;color:#000000;font-weight:bold; text-decoration:underline;\">Read Less&gt;</td><td valign=\"top\" width=\"20\"><table class=\"em_bg\" width=\"20\" align=\"center\" style=\"border-radius:50%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr></tr></table></td><td width=\"10\">&nbsp;</td></tr></table></td></tr><tr><td width=\"100%\" height=\"15\" style=\"font-size:0px; line-height:15px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></div></a></td></tr></table></td></tr></table></td></tr></table></td></tr></table></td></tr><tr bgcolor=\"#ffb91b\"><td width=\"100%\" height=\"5\" style=\"font-size:0px; line-height:5px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td></tr></table></div></td></table></td></tr></table><!--<![endif]--><!-- HERO END--><!-- START WARNING_RESPONSIVE MODULE --><table class=\"deviceWidth\" width=\"600\" align=\"center\" style=\"margin:0 auto;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><!--[if !mso]><!--><div class=\"show\" style=\"display:none;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr class=\"me\" style=\"width:0; overflow:hidden; float:left; display:none; max-height:0px; mso-hide:all;\"><td align=\"center\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"em_hide\" width=\"12\"></td><td align=\"center\" valign=\"top\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" height=\"5\" style=\"font-size:0px; line-height:5px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td align=\"center\" valign=\"top\"><table width=\"96%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td height=\"3\" style=\"line-height:1px; font-size:1px;\">&nbsp;</td></tr></table><table class=\"isi\" width=\"96%\" align=\"center\" style=\"border:2px solid #000000\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\" valign=\"top\"><table class=\"accordionShow\" id=\"partVisible2\" width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr height=\"2\"><td></td></tr><tr><td width=\"8\"></td><td><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><a href=\"#partVisible2\" style=\"display:block; text-decoration:none; color:inherit;\"><div><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"left\" valign=\"top\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"accordion-text test\" align=\"center\" style=\"padding: 0 14px 0 0px;\">WARNING: EMBRYO-FETAL TOXICITY,\n<br>TOXICITY, and VENOUS and\n<br>THROMBOEMBOLISM</td></tr><tr><td width=\"100%\" height=\"9\" style=\"font-size:0px; line-height:9px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td class=\"accordion-text test\" align=\"center\" style=\"font-style:italic; padding: 0 14px 0 0px;\">See full prescribing information for complete boxed warning.\n</td></tr><tr><td class=\"accordion-text u\" style=\"padding: 10px 14px 0 0;\">EMBRYO-FETAL TOXICITY\n</td></tr><tr><td style=\"padding: 4px 2px 0 0;\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"pdb\" valign=\"top\" style=\"padding-right:2px;\">&bull;</td><td class=\"pdb\" valign=\"top\">Lenalidomide, a thalidomide analogue, caused\n</td></tr></table></td></tr></table></td></tr><tr><td valign=\"top\"><table width=\"100%\" align=\"right\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"readMore\" align=\"right\" valign=\"middle\" style=\"padding-right:0;\">&nbsp;</td></tr></table></td></tr></table></td></tr></table></div></a></td></tr><tr><td><div class=\"outerHidden\"><div class=\"innerHidden\"><table width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\" valign=\"top\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"accordion-text\" valign=\"top\" style=\"padding-right:7px;\"></td><td class=\"accordion-text\" valign=\"top\">limb abnormalities in a developmental monkey study similar to birth defects caused\n  by thalidomide in humans. If lenalidomide is used\n  during pregnancy, it may cause birth defects or\n  embryo-fetal death.</td></tr></table></td></tr><tr><td style=\"padding: 0 2px 2px 0;\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"accordion-text\" valign=\"top\" style=\"padding-right:2px;\">&bull;</td><td class=\"accordion-text\" valign=\"top\">Pregnancy must be excluded before start of treatment.\nPrevent pregnancy during treatment by the use of two reliable methods of contraception.</td></tr></table></td></tr><tr><td height=\"10\" style=\"line-height:10px; font-size:1px;\">&nbsp;</td></tr><tr><td class=\"accordion-text\">REVLIMID is available only through a restricted distribution\n  program called the REVLIMID REMS\n  <sup style=\"font-size: 70%; line-height: 0; vertical-align: 5px;\">&reg;</sup>\n  <br>program.</td></tr><tr><td height=\"10\" style=\"line-height:10px; font-size:1px;\">&nbsp;</td></tr><tr><td class=\"accordion-text\"><span class=\"u\" style=\"text-decoration: underline;\">HEMATOLOGIC TOXICITY</span>.\n  REVLIMID can cause significant neutropenia and thrombocytopenia.</td></tr><tr><td style=\"padding: 2px 0 4px 0;\"><table width=\"100%\" align=\"center\">REVLIMID can<tr><td class=\"accordion-text\" valign=\"top\" style=\"padding-right:2px;\">&bull;</td><td class=\"accordion-text\" valign=\"top\">For patients with del 5q myelodysplastic syndromes, monitor\n  complete blood counts weekly for the first 8 weeks and monthly thereafter.</td></tr></table></td></tr><tr><td height=\"10\" style=\"line-height:10px; font-size:1px;\">&nbsp;</td></tr><tr><td class=\"accordion-text u\">VENOUS AND ARTERIAL THROMBOEMBOLISM</td></tr><tr><td style=\"padding: 2px 0 4px 0;\"><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"accordion-text\" valign=\"top\" style=\"padding-right:2px;\">&bull;</td><td class=\"accordion-text\" valign=\"top\">Significantly increased risk of deep vein thrombosis\n  (DVT) and pulmonary embolism(PE), as well as risk\n  of myocardial infarction and stroke in patients\n  with multiple myeloma receiving REVLIMID with dexamethasone.\n  Anti-thrombotic prophylaxis is recommended.\n\n\n\n</td></tr></table></td></tr></table></td></tr></table></div></div></td></tr></table></td><td width=\"10\"></td></tr></table><table class=\"close\" width=\"100%\" align=\"center\" style=\"display: none;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"right\"><a class=\"accordionShow\" href=\"#adv\" width=\"100%\" style=\"display:block; text-decoration:none; color:inherit;font-family: Arial, Helvetica, sans-serif; font-size: 14px; font-weight: normal; line-height: 1.3; font-weight: bold; text-decoration: underline; padding-right:10px;\">Read Less &gt;</a></td><td width=\"10\"></td></tr></table><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td height=\"8\"></td></tr></table></td></tr></table></td></tr><tr><td width=\"100%\" height=\"2\" style=\"font-size:0px; line-height:2px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td width=\"100%\" height=\"10\" style=\"font-size:0px; line-height:10px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td><td class=\"em_hide\" width=\"12\"></td></tr></table></td></tr></table></div><!--<![endif]--></td></tr></table><table class=\"deviceWidth\" width=\"620\" align=\"center\" style=\"margin:0 auto;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"zeroPadding\" valign=\"top\" style=\"padding:0\" bgcolor=\"#ffffff\"><table class=\"mobileWidth\" align=\"center\" width=\"100%\" bgcolor=\"#f1b720\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" height=\"6\" style=\"font-size:0px; line-height:6px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td><table bgcolor=\"#1eb5e3\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" height=\"18\" style=\"font-size:0px; line-height:18px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td><table class=\"mobileWidth\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"10\" height=\"11\" style=\"font-size:0px; line-height:11px;mso-line-height-rule:exactly;\">&nbsp;</td><td align=\"center\"><table class=\"mobileWidth\" align=\"center\" width=\"100%\"><tr><td align=\"center\"><font class=\"mobile_font_1 mobile_line_height\" width=\"auto\" style=\"font-family: 'Roboto', Helvetica, Arial, sans-serif; font-weight: 700; color: #ffffff; font-size: 27px; line-height:30px; text-decoration:none !important; text-decoration:none;\">REVLIMID maintenance therapy may extend</font></td></tr><tr><td align=\"center\"><font class=\"mobile_font_1 mobile_line_height\" width=\"auto\" style=\"font-family: 'Roboto', Helvetica, Arial, sans-serif; font-weight: 700; color: #ffffff; font-size: 27px; line-height:30px; text-decoration:none !important; text-decoration:none;\">PFS for your post auto-HSCT patients</font></td></tr><tr><td align=\"center\"><table class=\"mobileWidth\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"10\" height=\"9\" style=\"font-size:0px; line-height:9px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td width=\"10\" height=\"12\" style=\"font-size:0px; line-height:12px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td></tr></table></td><td width=\"10\" height=\"14\" style=\"font-size:0px; line-height:14px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td></tr></table></td></tr></table></td></tr></table><!-- END WARNING_RESPONSIVE MODULE --><!-- START BODY MODULE --><table class=\"deviceWidth\" width=\"600\" align=\"center\" style=\"margin:0 auto;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td style=\"padding:0 0 0 0; vertical-align: top;\"><table class=\"deviceWidth\" align=\"left\" width=\"400\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" height=\"23\" style=\"font-size:0px; line-height:23px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td align=\"center\"><img src=\"img/body/REVLIMID_placebo.jpg\" width=\"306\" height=\"64\"></td></tr><tr><td width=\"100%\" height=\"23\" style=\"font-size:0px; line-height:23px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td class=\"padding12\" style=\"padding-left: 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"font-size: 15px;padding-right: 2px; vertical-align: 4px; vertical-align: top; font-weight: bold;color: #4fc6ea;\">â¢</td><td class=\"p\" align=\"left\" style=\"font-size: 14px;color:#004b7e;padding: 0 0 6px 0; text-align:left;font-family: 'Roboto', Helvetica, sans-serif;font-weight: 400;line-height: 1.3\"><font>In Study 1 (US), median progression-free survival (PFS) at unblinding<sup style=\"vertical-align:3px!important;position:relative; color:#004b7e; text-align:left;font-family: Roboto, Helvetica, sans-serif;font-weight: 400;font-size:12px;\">*</sup> was 2.8 years for REVLIMID vs 1.6  years for placebo (HR 0.38; 95% CI 0.27, 0.54; <span style=\"font-style: italic;\">P</span>&lt;0.001)<sup>1,2</sup></font></td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding-left: 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"font-size: 15px;padding-right: 2px; vertical-align: 4px; vertical-align: top; font-weight: bold;color: #4fc6ea;\">â¢</td><td class=\"p\" align=\"left\" style=\"font-size: 14px;color:#004b7e;padding: 0 0 6px 0; text-align:left;font-family: 'Roboto', Helvetica, sans-serif;font-weight: 400;line-height: 1.3\"><font>In Study 2 (EU), median PFS at unblinding<sup style=\"vertical-align:3px!important;position:relative; color:#004b7e;text-align:left;font-family: Roboto, Helvetica, sans-serif;font-weight: 400;font-size:12px;\">*</sup> was 3.4 years for REVLIMID vs 1.9 years for placebo (HR 0.50; 95% CI 0.39, 0.64; <span style=\"font-style: italic;\">P </span>&lt;0.001)<sup>1,2</sup></font></td></tr></table></td></tr><tr><td width=\"100%\" height=\"20\" style=\"font-size:0px; line-height:20px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td><table bgcolor=\"#1eb5e3\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" height=\"10\" style=\"font-size:0px; line-height:10px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td><table class=\"mobileWidth\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"10\" height=\"11\" style=\"font-size:0px; line-height:11px;mso-line-height-rule:exactly;\">&nbsp;</td><td align=\"center\"><table class=\"mobileWidth\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\"><font class=\"mobile_font_1 mobile_line_height\" width=\"auto\" style=\"font-family: 'Roboto', Helvetica, sans-serif; font-weight: 700; color: #ffffff; font-size: 16px; line-height:19px; text-decoration:none !important; text-decoration:none;\">Median PFS<sup style=\"font-size:11.2px;\">â </sup> at Updated Analysis<sup style=\"font-size:11.2px;\">â¡</sup> for<br> Maintenance Studies 1 and 2<sup style=\"font-size:11.2px;\">1,2</sup>\n</font></td></tr></table></td><td width=\"10\" height=\"14\" style=\"font-size:0px; line-height:14px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td></tr><tr><td width=\"100%\" height=\"13\" style=\"font-size:0px; line-height:13px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td></tr><tr><td valign=\"top\" bgcolor=\"#c7edf8\"><div class=\"hide\"><img src=\"img/body/img_pfs_chart.jpg\" alt=\"PFS in study 1\" style=\"max-width: 100%; width: 100%;\"></div><!--[if !mso]><!--><div class=\"show\" style=\"display: none;\"><img src=\"img/body/img_pfs_chart_mob.jpg\" alt=\"PFS in study 1\" style=\"max-width: 100%; width: 100%;\"></div><!--<![endif]--></td></tr><tr bgcolor=\"#d2f0f9\"><td class=\"padding12\" style=\"padding-left: 20px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"7\" valign=\"top\" class=\"bullet\" style=\"text-align:right;font-size: 14px;padding-right: 0px; vertical-align: 4px; vertical-align: top; font-weight: 400;color:#004b7e;\"><sup style=\"padding-right:1px;\">*</sup></td><td align=\"left\" style=\"color:#004b7e; padding: 0 15px 6px 0px; text-align:left;font-family: 'Roboto', Helvetica, sans-serif;font-weight: 400;line-height: 1;font-size:12px;\"><font>Study 1: Unblinded December 2009; Study 2: Unblinded July 2010.\n</font></td></tr></table></td></tr><tr bgcolor=\"#d2f0f9\"><td class=\"padding12\" style=\"padding-left: 20px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"7\" valign=\"top\" class=\"bullet\" style=\"text-align:right;font-size: 14px;padding-right: 0px; vertical-align: 4px; vertical-align: top; font-weight: 400;color:#004b7e;\"><sup>â </sup></td><td align=\"left\" style=\"color:#004b7e; padding: 0 15px 6px 0px; text-align:left;font-family: 'Roboto', Helvetica, sans-serif;font-weight: 400;line-height: 1;font-size:12px;\"><font>PFS was defined from randomization to the date of progression or death, whichever occurred first.\n</font></td></tr></table></td></tr><tr bgcolor=\"#d2f0f9\"><td class=\"padding12\" style=\"padding-left: 20px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"7\" valign=\"top\" class=\"bullet\" style=\"text-align:right;font-size: 14px;padding-right: 0px; vertical-align: 4px; vertical-align: top; font-weight: 400;color:#004b7e;\"><sup>â¡</sup></td><td align=\"left\" style=\"color:#004b7e; padding: 0 15px 6px 0px; text-align:left;font-family: 'Roboto', Helvetica, sans-serif;font-weight: 400;line-height: 1;font-size:12px;\"><font>Updated analysis conducted in March 2015.\n</font></td></tr></table></td></tr><tr bgcolor=\"#d2f0f9\"><td width=\"100%\" height=\"15\" style=\"font-size:0px; line-height:15px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td width=\"100%\" height=\"23\" style=\"font-size:0px; line-height:23px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td align=\"center\"><img src=\"img/body/OverallSurvival.jpg\" width=\"306\" height=\"64\"></td></tr><tr><td width=\"100%\" height=\"23\" style=\"font-size:0px; line-height:23px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td><table bgcolor=\"#1eb5e3\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"100%\" height=\"10\" style=\"font-size:0px; line-height:10px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td><table class=\"mobileWidth\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"10\" height=\"11\" style=\"font-size:0px; line-height:11px;mso-line-height-rule:exactly;\">&nbsp;</td><td align=\"center\"><table class=\"mobileWidth\" align=\"center\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\"><font class=\"mobile_font_1 mobile_line_height\" width=\"auto\" style=\"font-family: 'Roboto', Helvetica, sans-serif; font-weight: 700; color: #ffffff; font-size: 16px; line-height:20px; text-decoration:none !important; text-decoration:none;\">Median Overall Survival for<br> Maintenance Studies 1 and 2<sup style=\"font-size:11.2px;\">1,2</sup>\n</font></td></tr></table></td><td width=\"10\" height=\"10\" style=\"font-size:0px; line-height:10px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td></tr><tr><td width=\"100%\" height=\"13\" style=\"font-size:0px; line-height:13px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td></tr><tr><td valign=\"top\" bgcolor=\"#c7edf8\"><div class=\"hide\"><img src=\"img/body/img_os_chart.jpg\" alt=\"PFS in study 1\" style=\"max-width: 100%; width: 100%;\"></div><!--[if !mso]><!--><div class=\"show\" style=\"display: none;\"><img src=\"img/body/img_os_chart_mob.jpg\" alt=\"PFS in study 1\" style=\"max-width: 100%; width: 100%;\"></div><!--<![endif]--></td></tr><tr bgcolor=\"#c7edf8\"><td class=\"padding12\" style=\"padding-left: 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" align=\"top\" style=\"padding:0px 2px 6px 0; text-align:left;font-family: 'Roboto', Helvetica, sans-serif;font-weight: 400;line-height: 1;font-size:17px;\">â¢</td><td align=\"left\" style=\"color:#004b7e;padding:0px 0 15px 0; text-align:left;font-family: 'Roboto', Helvetica, sans-serif;font-weight: 400;line-height: 1;font-size:14px;\"><font>The individual studies were not powered to evaluate OS</font></td></tr></table></td></tr><tr><td width=\"100%\" height=\"15\" style=\"font-size:0px; line-height:15px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td style=\"padding-bottom: 2px; font-size:14px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12\" style=\"color:#004b7e;padding: 0 15px 0 15px;text-align:left;line-height: 1.4;\"><font>Descriptive analysis of OS data with a cutoff date of February 1, 2016 is provided above. Median follow-up time was 81.6 and 96.7 months for Maintenance Study 1 and Maintenance Study 2, respectively.</font></td></tr></table></td></tr><tr><td width=\"100%\" height=\"12\" style=\"font-size:0px; line-height:12px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table></td><td class=\"hide\" style=\"padding:0 0 0 0; vertical-align: top;\"><table class=\"deviceWidth\" align=\"left\" width=\"210\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td style=\"vertical-align: top; padding:0 4px 0 8px\"><table><tr><td class=\"p\" align=\"left\" style=\"font-weight:700;color:#004b7e;padding: 12px 0 8px 0\"><a href=\"https://www.celgenepatientsupport.com\"><img src=\"img/body/celgeneLearnMore.jpg\" style=\"width: 100%;max-width: 100%;\"></a></td></tr><tr><td style=\"border: solid 2px #000000; width:100%\"><table width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td valign=\"top\" style=\"padding:8px 7px 8px 7px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"center\" style=\"padding-bottom:8px; font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 12px;font-weight: 700;\">WARNING: EMBRYO-FETAL\n<br> TOXICITY, HEMATOLOGIC\n<br> TOXICITY, and VENOUS and\n<br> ARTERIAL THROMBOEMBOLISM\n</td></tr><tr><td align=\"center\" style=\"font-weight:700;font-style:italic;padding-bottom:12px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">See full prescribing information for complete boxed warning.\n</td></tr><tr><td class=\"u\" style=\"font-weight:700;padding-bottom:4px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;text-decoration: underline;\">EMBRYO-FETAL TOXICITY</td></tr><tr><td valign=\"top\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"padding-right:2px;vertical-align: top !important;color: black; font-size: 14px;\">â¢</td><td align=\"left\" style=\"font-weight: 700;padding-bottom: 2px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Lenalidomide, a thalidomide analogue, caused limb abnormalities\n  in a developmental monkey study similar to birth\n  defects caused by thalidomide in humans. If lenalidomide\n  is used during pregnancy, it may cause birth defects or embryo-fetal death.</td></tr><tr><td class=\"bullet\" valign=\"top\" style=\"padding-right:2px;color: #000; font-size: 14px;\">â¢</td><td align=\"left\" style=\"font-weight: 700;padding-bottom: 12px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Pregnancy must be excluded before start of treatment. Prevent pregnancy during treatment by the use of two reliable methods\nof contraception.</td></tr></table></td></tr><tr><td align=\"left\" style=\"font-weight: 700;padding-bottom:12px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">REVLIMID is available only through a restricted distribution program called the REVLIMID REMS<sup>&reg;</sup> program.</td></tr><tr><td style=\"font-weight:700;padding-bottom:4px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\"><span class=\"u\" style=\"text-decoration: underline;\">HEMATOLOGIC TOXICITY</span>.</td></tr><tr><td style=\"font-weight: 700;padding-bottom:2px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">REVLIMID can cause significant neutropenia and thrombocytopenia.</td></tr><tr><td valign=\"top\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"padding-right:2px;color: #000; font-size: 14px;\">â¢</td><td align=\"left\" style=\"font-weight: 700;padding-bottom: 12px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">For patients with del 5q myelodysplastic syndromes, monitor\n  complete blood counts weekly for the first 8 weeks\n  and monthly thereafter.\n</td></tr></table></td></tr><tr><td class=\"u\" style=\"font-weight:700;padding-bottom:2px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;text-decoration: underline;\">VENOUS AND ARTERIAL THROMBOEMBOLISM</td></tr><tr><td valign=\"top\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"padding-right:2px;color: black; font-size: 14px;\">â¢</td><td align=\"left\" style=\"font-weight:700;padding-bottom: 8px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Significantly increased risk of deep vein thrombosis\n  (DVT) and pulmonary embolism (PE), as well as risk\n  of myocardial infarction and stroke in patients with\n  multiple myeloma receiving REVLIMID with dexamethasone.\n  Anti-thrombotic prophylaxis is recommended.\n</td></tr></table></td></tr></table></td></tr></table></td></tr><tr><td align=\"left\" style=\"font-size: 13px;font-weight:700;color:#004b7e;padding: 5px 0 5px 8px;\">See Important Safety <br>Information below.</td></tr><tr><td align=\"left\" style=\"font-size: 13px;font-weight:700;color:#004b7e;padding: 0 0 5px 8px;\">Please see full <a href=\"http://www.celgene.com/content/uploads/revlimid-pi.pdf\" style=\"color:#004b7e;\"><br>Prescribing Information</a>, <br>including Boxed WARNINGS.</td></tr></table></td></tr></table></td></tr></table><!-- END BODY MODULE --><!-- START SAFETY MODULE --><table class=\"deviceWidth\" width=\"600\" align=\"center\" style=\"margin:0 auto;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table><tr><td></td><td style=\"height:10px;\" height=\"10\">&nbsp;</td></tr></table></td></tr><tr><td><a href=\"http://www.revlimid.com/mm-hcp/expanded-indication/?utm_source=appature&amp;utm_medium=email&amp;utm_campaign=maintenance_efficacy&amp;utm_content=post_auto_hsct\"><img src=\"img/body/icon_arrow.jpg\" style=\"width: 100%;max-width: 100%;\"></a></td></tr><tr><td></td><td style=\"height:10px;\" height=\"10\">&nbsp;</td></tr></table></td></tr><tr><td align=\"left\" style=\"line-height: 1;padding: 5px 15px 5px 15px;font-size: 23px;font-weight:700;color:#18bee7;font-family:'Roboto Condensed', Helvetica, Arial, sans-serif;\">Important Safety Information</td></tr><tr><td style=\"padding-bottom:15px;padding-left: 12px;padding-right: 12px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td style=\"border: solid 2px #000000; width:100%;\"><table width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"top\" style=\"padding:10px 10px 10px 10px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"p\" align=\"center\" style=\"font-weight:700;font-size:14px;padding-bottom:6px;font-family: 'Roboto', Helvetica, Arial, sans-serif;\">WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS and ARTERIAL THROMBOEMBOLISM\n</td></tr><tr><td style=\"text-decoration:underline;font-weight:700;padding-bottom:4px; padding-bottom:0px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Embryo-Fetal Toxicity\n</td></tr><tr><td valign=\"top\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td align=\"left\" style=\"font-weight: 700;padding-bottom: 12px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program, the REVLIMID REMS<sup>Â®</sup> program.</td></tr><tr><td align=\"left\" style=\"font-weight:700;padding-bottom: 12px; font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Information about the REVLIMID REMS<sup>Â®</sup> program is available at <a href=\"https://www.celgeneriskmanagement.com/REMSPortal/rems/portal/REMSPortal.portal\" style=\"font-size: 14px;color: #004b7e\">www.celgeneriskmanagement.com</a> or by calling the manufacturerâs toll-free number <br><span style=\"color:#000\">1-888-423-5436</span>.\n</td></tr></table></td></tr><tr><td align=\"left\" style=\"text-decoration:underline;font-weight:700;padding-bottom:0px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Hematologic Toxicity (Neutropenia and Thrombocytopenia)\n</td></tr><tr><td style=\"font-weight:700;padding-bottom:12px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q MDS had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors.\n</td></tr><tr><td align=\"left\" style=\"text-decoration:underline;font-weight:700;padding-bottom:0px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">Venous and Arterial Thromboembolism\n</td></tr><tr><td style=\"font-weight:700;padding-bottom:10px;font-family: 'Roboto', Helvetica, Arial, sans-serif; font-size: 14px;\">REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients about signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice of regimen should be based on an assessment of the patientâs underlying risks.\n\n</td></tr></table></td></tr></table></td></tr></table></td></tr><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;font-weight:700;color:#18bee7;padding:0 0 5px 30px;font-family: Arial, Helvetica, sans-serif;\">CONTRAINDICATIONS</td></tr><tr><td class=\"padding12\" style=\"padding: 0 42px 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"p\" align=\"left\" style=\"padding-bottom: 10px; font-family: Arial, Helvetica, sans-serif;\"><span style=\"font-weight:700;\">Pregnancy:</span> REVLIMID can cause fetal harm when administered\n  to a pregnant female and is contraindicated in females who are pregnant. If this drug\n  is used during pregnancy or if the patient becomes pregnant while taking this drug, the\n  patient should be apprised of the potential risk to the fetus\n</td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding: 0 42px 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"p\" align=\"left\" style=\"padding-bottom: 10px;font-size: 14px;line-height: 1.2;font-family: Arial, Helvetica, sans-serif; font-weight: 400;\"><span style=\"font-weight:700;\">Allergic Reactions:</span> REVLIMID is contraindicated in patients\n  who have demonstrated hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic\n  epidermal necrolysis) to lenalidomide\n</td></tr></table></td></tr><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;font-weight:700;color:#18bee7;padding:0 0 5px 30px; font-family: Arial, Helvetica, sans-serif;\">WARNINGS AND PRECAUTIONS\n</td></tr><tr><td><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:0 0 6px 30px;font-weight:700; font-family: Arial, Helvetica, sans-serif;\">Embryo-Fetal Toxicity: See Boxed WARNINGS\n</td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding: 0 30px 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"font-size: 15px;padding-right: 2px; vertical-align: 4px; vertical-align: top; font-weight: bold;color: #4fc6ea;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom:8px;font-family: Arial, Helvetica, sans-serif; font-weight: 400;\"><span style=\"text-decoration:underline;\">Females of Reproductive Potential</span>:\n<span style=\"font-weight:700;\">See Boxed WARNINGS</span>\n</td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding: 0 30px 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"font-size: 15px;padding-right: 2px; vertical-align: 4px; vertical-align: top; font-weight: bold;color: #4fc6ea;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom:8px;font-family: Arial, Helvetica, sans-serif; font-weight: 400;\"><span style=\"text-decoration:underline;\">Males</span>: Lenalidomide is present in the semen\n  of patients receiving the drug. Males must always use a latex or synthetic condom during\n  any sexual contact with females of reproductive potential while taking REVLIMID and for\n  up to 4 weeks after discontinuing REVLIMID, even if they have undergone a successful\n  vasectomy. Male patients taking REVLIMID must not donate sperm\n</td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding: 0 30px 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet\" valign=\"top\" style=\"font-size: 15px;padding-right: 2px; vertical-align: 4px; vertical-align: top; font-weight: bold;color: #4fc6ea;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom:8px;font-family: Arial, Helvetica, sans-serif; font-weight: 400;\"><span style=\"text-decoration:underline;\">Blood Donation</span>: Patients must not donate blood\n  during treatment with REVLIMID and for 4 weeks following discontinuation of the drug\n  because the blood might be given to a pregnant female patient whose fetus must not be\n  exposed to REVLIMID\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">REVLIMID REMS<sup>Â®</sup> Program: See Boxed WARNINGS:</span> Prescribers and pharmacies must be certified with the REVLIMID REMS program by enrolling and complying with the REMS requirements; pharmacies must only dispense to patients who are authorized to receive REVLIMID. Patients must sign a Patient-Physician Agreement Form and comply with REMS requirements; female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements and males must comply with contraception requirements\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Hematologic Toxicity:</span> REVLIMID can cause significant neutropenia and thrombocytopenia. Monitor patients with neutropenia for signs of infection. Advise patients to observe for bleeding or bruising, especially with use of concomitant medications that may increase risk of bleeding. <span style=\"font-weight:bold;text-decoration:underline;\">MM</span>: Patients taking REVLIMID/dex or REVLIMID as maintenance therapy should have their complete blood counts (CBC) assessed every 7 days for the first 2 cycles, on days 1 and 15 of cycle 3, and every 28 days thereafter \n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Venous and Arterial Thromboembolism: See Boxed WARNINGS: </span>Venous thromboembolic events (DVT and PE) and arterial thromboses (MI and CVA) are increased in patients treated with REVLIMID. Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended and the regimen should be based on patient's underlying risks. ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Increased Mortality in Patients with CLL:</span> In a clinical trial in the first-line treatment of patients with CLL, single agent REVLIMID therapy increased the risk of death as compared to single agent chlorambucil. Serious adverse cardiovascular reactions, including atrial fibrillation, myocardial infarction, and cardiac failure, occurred more frequently in the REVLIMID arm. REVLIMID is not indicated and not recommended for use in CLL outside of controlled clinical trials\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Second Primary Malignancies (SPM):</span> In clinical trials in patients with MM receiving REVLIMID, an increase of hematologic plus solid tumor SPM, notably AML and MDS, have been observed. Monitor patients for the development of SPM. Take into account both the potential benefit of REVLIMID and risk of SPM when considering treatment\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Hepatotoxicity:</span> Hepatic failure, including fatal cases, has occurred in patients treated with REVLIMID/dex. Pre-existing viral liver disease, elevated baseline liver enzymes, and concomitant medications may be risk factors. Monitor liver enzymes periodically. Stop REVLIMID upon elevation of liver enzymes. After return to baseline values, treatment at a lower dose may be considered\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Allergic Reactions:</span> Angioedema and serious dermatologic reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. These events can be fatal. Patients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive REVLIMID. REVLIMID interruption or discontinuation should be considered for Grade 2-3 skin rash. REVLIMID must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if SJS or TEN is suspected and should not be resumed following discontinuation for these reactions. REVLIMID capsules contain lactose; risk-benefit of treatment should be evaluated in patients with lactose intolerance\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Tumor Lysis Syndrome (TLS):</span> Fatal instances of TLS have been reported during treatment with lenalidomide. The patients at risk of TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Tumor Flare Reaction (TFR):</span> TFR has occurred during investigational use of lenalidomide for CLL and lymphoma. Monitoring and evaluation for TFR is recommended in patients with MCL. Tumor flare may mimic the progression of disease (PD). In patients with Grade 3 or 4 TFR, it is recommended to withhold treatment with REVLIMID until TFR resolves to â¤Grade 1. REVLIMID may be continued in patients with Grade 1 and 2 TFR without interruption or modification, at the physicianâs discretion\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Impaired Stem Cell Mobilization:</span> A decrease in the number of CD34+ cells collected after treatment (>4 cycles) with REVLIMID has been reported. Consider early referral to transplant center to optimize timing of the stem cell collection\n</td></tr></table></td></tr><tr><td style=\"padding-right: 24px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:10px 0 5px 30px;\"><span style=\"font-weight:700;\">Thyroid Disorders:</span> Both hypothyroidism and hyperthyroidism have been reported. Measure thyroid function before start of REVLIMID treatment and during therapy \n</td></tr></table></td></tr><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;font-weight:700;color:#18bee7;padding:10px 0 5px 30px;\">ADVERSE REACTIONS\n</td></tr><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;font-weight:700;padding:0 0 5px 30px;text-decoration:underline;\">Multiple Myeloma\n</td></tr><tr><td class=\"padding12\" style=\"padding-left:30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"0\" style=\"width:0px;color:#ffffff;font-size:1px;\">.&nbsp;</td><td class=\"bullet bullet_mobile bullet_desktop\" valign=\"top\" style=\"padding-right: 2px; font-size: 15px; vertical-align: 4px; vertical-align: top; font-weight: bold; color:#18bee7;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom: 10px;text-align:left;\"><font><span style=\"font-weight:700;\">Maintenance Therapy Post-Auto HSCT:</span> The most frequently\n  reported Grade 3 or 4 reactions in â¥20% (REVLIMID arm) included neutropenia, thrombocytopenia,\n  and leukopenia. The serious adverse reactions of lung infection and neutropenia (more\n  than 4.5%) occurred in the REVLIMID arm\n</font></td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding-left:30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td width=\"0\" style=\"width:0px;color:#ffffff;font-size:1px;\">.&nbsp;</td><td class=\"bullet bullet_mobile bullet_desktop\" valign=\"top\" style=\"padding-right: 2px; font-size: 15px; vertical-align: 4px; vertical-align: top; font-weight: bold; color:#18bee7;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom: 2px;text-align:left;\"><font>The most frequently reported adverse reactions in â¥20% (REVLIMID arm) across both maintenance\nstudies (Study 1, Study 2) were neutropenia (79%, 61%), thrombocytopenia (72%, 24%),\nleukopenia (23%, 32%), anemia (21%, 9%), upper respiratory tract infection (27%,\n11%), bronchitis (5%, 47%), nasopharyngitis (2%, 35%), cough (10%, 27%), gastroenteritis\n(0%, 23%), diarrhea (55%, 39%), rash (32%, 8%), fatigue (23%, 11%), asthenia (0%,\n30%), muscle spasm (0%, 33%), and pyrexia (8%, 21%)\n\n</font></td></tr></table></td></tr><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding: 10px 0 5px 30px;font-weight:700;color:#18bee7;\">DRUG INTERACTIONS</td></tr><tr><td class=\"padding12\" style=\"padding: 0px 30px 0px 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"p\" align=\"left\" style=\"padding-bottom: 16px;\">Periodic monitoring of digoxin plasma levels is recommended due to increased C<span style=\"font-size:75%; vertical-align: -6px;\">max</span>                                    and AUC with concomitant REVLIMID therapy. Patients taking concomitant therapies such\n  as erythropoietin stimulating agents or estrogen containing therapies may have an increased\n  risk of thrombosis. It is not known whether there is an interaction between dex and warfarin.\n  Close monitoring of PT and INR is recommended in patients with MM taking concomitant\n  warfarin\n</td></tr></table></td></tr><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;padding:0 0 5px 30px;font-weight:700;color:#18bee7;\">USE IN SPECIFIC POPULATIONS\n</td></tr><tr><td class=\"padding12\" style=\"padding:10px 0 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet bullet_mobile bullet_desktop\" valign=\"top\" style=\"padding-right: 2px; font-size: 15px; vertical-align: 4px; vertical-align: top; font-weight: bold; color:#18bee7;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom: 2px;text-align:left;\"><font><span style=\"font-weight:700;color:#18bee7;\">PREGNANCY:</span>\n<span style=\"font-weight:700;\">See Boxed WARNINGS:</span> If pregnancy does occur\nduring treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist\nexperienced in reproductive toxicity for further evaluation and counseling. There\nis a REVLIMID pregnancy exposure registry that monitors pregnancy outcomes in females\nexposed to REVLIMID during pregnancy as well as female partners of male patients\nwho are exposed to REVLIMID. This registry is also used to understand the root cause\nfor the pregnancy. Report any suspected fetal exposure to REVLIMID to the FDA via\nthe MedWatch program at <a class=\"tel_link\" href=\"tel://1-800-332-1088\" target=\"_blank\" style=\"color:#000;text-decoration:none;\">1-800-FDA-1088</a> and also to Celgene Corporation at <a class=\"tel_link\" href=\"tel://1-888-423-5436\" target=\"_blank\" style=\"color:#000;text-decoration:none;\">1-888-423-5436</a>\n</font></td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding:10px 0 0px 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet bullet_mobile bullet_desktop\" valign=\"top\" style=\"padding-right: 2px; font-size: 15px; vertical-align: 4px; vertical-align: top; font-weight: bold; color:#18bee7;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom: 2px;text-align:left;\"><font><span style=\"font-weight:700;color:#18bee7;\">LACTATION:</span> There is no information\nregarding the presence of lenalidomide in human milk, the effects of REVLIMID on\nthe breastfed infant, or the effects of REVLIMID on milk production. Because many\ndrugs are excreted in human milk and because of the potential for adverse reactions\nin breastfed infants from REVLIMID, advise female patients not to breastfeed during\ntreatment with REVLIMID]\n</font></td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding:10px 0 0px 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet bullet_mobile bullet_desktop\" valign=\"top\" style=\"padding-right: 2px; font-size: 15px; vertical-align: 4px; vertical-align: top; font-weight: bold; color:#18bee7;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom: 2px;text-align:left;\"><font><span style=\"font-weight:700;color:#18bee7;\">PEDIATRIC USE:</span> Safety and effectiveness\nhave not been established in pediatric patients]\n</font></td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding:10px 0 0px 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"bullet bullet_mobile bullet_desktop\" valign=\"top\" style=\"padding-right: 2px; font-size: 15px; vertical-align: 4px; vertical-align: top; font-weight: bold; color:#18bee7;\">â¢</td><td class=\"p\" align=\"left\" style=\"padding-bottom: 2px;text-align:left;\"><font><span style=\"font-weight:700;color:#18bee7;\">RENAL IMPAIRMENT:</span> Adjust the starting\ndose of REVLIMID based on creatinine clearance value and in patients on dialysis]\n</font></td></tr></table></td></tr><tr><td class=\"padding12 p\" style=\"font-size: 14px;line-height: 1.2;font-weight:700;padding:10px 42px 8px 30px;text-align:left;\">Please see full <a href=\"http://www.celgene.com/content/uploads/revlimid-pi.pdf\" target=\"_blank\" style=\"color:#18bee7;\">Prescribing Information</a>,\nincluding Boxed WARNINGS.</td></tr><tr><td width=\"100%\" height=\"30\" style=\"font-size:0px; line-height:30px;mso-line-height-rule:exactly;\">&nbsp;</td></tr><tr><td class=\"padding12 p\" align=\"left\" style=\"font-size: 14px;line-height: 1.2;font-weight:700;padding:10px 0 5px 30px;\">References:\n</td></tr><tr><td class=\"padding12\" style=\"padding: 0 0 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"p\" align=\"left\" style=\"padding-bottom: 2px;text-align:left;\"><font>1. REVLIMID [package insert]. Summit, NJ:\n<!--[if !mso]><!-->\n<br class=\"show\" style=\"display:none;\">\n<!--<![endif]--> Celgene Corp; 2017.\n\n</font></td></tr></table></td></tr><tr><td class=\"padding12\" style=\"padding: 0 0 0 30px;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"p\" align=\"left\" style=\"padding-bottom: 2px;text-align:left;\"><font>2. Data on file. Celgene Corp; 2017.</font></td></tr></table></td></tr><tr><td width=\"100%\" height=\"30\" style=\"font-size:0px; line-height:30px;mso-line-height-rule:exactly;\">&nbsp;</td></tr></table><!-- END SAFETY MODULE --><!-- START FOOTER MODULE --><table width=\"100%\" align=\"center\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td bgcolor=\"#e1e1e1\" style=\"padding:12px 0\"><table class=\"deviceWidth\" width=\"600\" border=\"0\" cellpadding=\"10\" cellspacing=\"0\" align=\"center\" style=\"padding:0 10px 0 10px;margin:0 auto;font-weight:normal;font-family: Arial, Helvetica, sans-serif;\"><tr><td><table class=\"deviceWidth\" width=\"85%\" align=\"left\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"footer\" valign=\"top\" style=\"padding-bottom:4px;font-weight:normal;font-family: Arial, Helvetica, sans-serif;\" align=\"left\">This e-mail was sent by Celgene Corporation and is intended for U.S. healthcare providers only.</td></tr><tr><td class=\"footer\" valign=\"top\" style=\"padding-bottom:4px;font-weight:normal;font-family: Arial, Helvetica, sans-serif;\" align=\"left\">Celgene Corporation,  <span class=\"mobile_link\">86 Morris Avenue, Summit, New Jersey 07901</span></td></tr><tr><td class=\"footer\" valign=\"top\" style=\"padding-bottom:4px;font-weight:normal;font-family: Arial, Helvetica, sans-serif;\" align=\"left\">To no longer receive these messages from Celgene about REVLIMID concerning multiple myeloma, <br>please <a href=\"http://www.celgenesubscriptioncenter.com/contacts/optout/25?key={{contact.email}}\" target=\"_blank\" style=\"text-decoration:underline;color:#004b7f;\">click here</a> to unsubscribe from this email list.</td></tr><tr><td class=\"footer\" valign=\"top\" align=\"left\">To manage your Celgene communications, <a href=\"http://www.celgenesubscriptioncenter.com/contacts/subscriptions?key={{contact.email}}\" target=\"_blank\" style=\"color:#004b7f;text-decoration:underline;\">click here</a>.\n</td></tr></table></td></tr><tr><td style=\"padding-bottom:0px;\"><table><tr><td class=\"logo-container\" valign=\"middle\" style=\"vertical-align: middle;\"><a href=\"http://www.celgene.com\"><img class=\"full-width\" src=\"img/footer/logoFooter.png\" width=\"90\" alt=\"Celgene\" border=\"0\" style=\"max-width: 100%;\"></a><br></td><td valign=\"middle\" style=\"vertical-align: middle;\" width=\"14px\">&nbsp;</td><td valign=\"middle\" style=\"vertical-align: middle;\"><table border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table class=\"foot_2 hide\" width=\"85%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td class=\"footer\" style=\"text-align:left;line-height: 1;padding-bottom:5px; font-size: 10px !important;\">REVLIMID<sup>&reg;</sup>, REVLIMID REMS<sup>&reg;</sup>, and Celgene Patient Support<sup>&reg;</sup> are registered trademarks of Celgene Corporation.</td></tr><tr><td><table class=\"hide \" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table class=\"hide \" width=\"100%\"><tr><td class=\"footer sixty\">Â© 2017 Celgene Corporation</td><td class=\"footer sixty\"><span class=\"sixty_s\" style=\"padding-right:25px;\">03/17</span> US-REV170037</td></tr></table></td></tr></table></td></tr></table><!--[if !mso]><!--><table class=\"show \" style=\"display:none;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\"><tr><td><table class=\"hide \" width=\"100%\"><tr><td class=\"footer sixty\">Â© 2017 Celgene Corporation</td><td class=\"footer sixty\"><span class=\"sixty_s\" style=\"padding-right:25px;\">03/17</span> US-REV170037</td></tr></table></td></tr></table><!--<![endif]--></td></tr></table></td></tr></table></td></tr></table></td></tr></table><!-- END FOOTER MODULE --><img src=\"https://www.google-analytics.com/collect?v=1&amp;amp;tid=UA-41110602-1&amp;amp;cid=02254587&amp;amp;t=event&amp;amp;ec=maintenance_efficacy&amp;amp;ea=open&amp;amp;el=open_email&amp;amp;cs=appature&amp;amp;cm=email&amp;amp;cn=open_email_tracking\" style=\"border:0;margin:0;\"></body></html>"